Ignite Creation Date:
2024-10-25 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06594965
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-10
Brief Title:
A Study of HS-20106 to Treat Anemia Due to Very Low Low or Intermediate Risk Myelodysplastic Syndromes
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase II Study on the Efficacy Safety and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk Low-risk or Moderate-risk Myelodysplastic Syndrome MDS Anemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy safety and pharmacokinetics of HS-20106 on anemia in patients with very low low or intermediate risk MDS
Detailed Description:
Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes an umbrella term used to describe disorders relating to the ineffective production of red blood cells white blood cells andor platelets The goal of this study is to assess the efficacy safety and PK of HS-20106 on anemia in Chinese patients with very low low or intermediate risk MDS Eligible subjects will be treated with HS-20106 Patients should be treated for at least 24 weeks in the core treatment period to assess their response to treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None